| Name | Title | Contact Details |
|---|---|---|
Coe Salzgeber |
Senior Director, Data & Infrastructure | Profile |
Lisa Hall |
Chief Information Security Officer | Profile |
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. Artiva Biotherapeutics was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, our mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva`s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that.
OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer.
RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.
Indevus Pharmaceuticals Inc. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.